US EditionPublished • loading... • Updated
Tirzepatide Safety Warning; Nurse Charged Over Fake GLP-1s; Revised Afrezza Dosing
FDA warns against sharing tirzepatide pens due to infection risk; nurse in Chicago charged with distributing counterfeit semaglutide; Afrezza dosing updated amid rising GLP-1 prescriptions.
Summary by MedPage Today
3 Articles
3 Articles
MedPage TodayReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsTirzepatide Safety Warning; Nurse Charged Over Fake GLP-1s; Revised Afrezza Dosing
(MedPage Today) -- Tirzepatide (Mounjaro, Zepbound) users should never share KwikPens due to risk for transmission of blood-borne pathogens, the FDA warned in an updated label. GLP-1 medications for weight loss accounted for more than 7% of all...
·New York, United States
Read Full Article
Are Compounded Semaglutide and Tirzepatide Safe?
Note: Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA) and may carry greater risks than FDA-approved treatments. Despite new rules limiting their manufacture, compounded GLP-1 drugs — off-brand formulations of semaglutide and tirzepatide, the active ingredients in the blockbuster diabetes and weight loss drugs Ozempic, Wegovy, Mounjaro, and Zepbound — are still widely available online and from alternative sources …
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
